Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab combined with lenvatinib for advanced primary liver cancer
ChiCTR2100052768Phase 2Recruiting
- Sponsor
- The 2nd Affiliated Hospital of Harbin Medical University
- Start
- Nov 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and lenvatinib in liver cancer and hepatocellular carcinoma (HCC), sponsored by The 2nd Affiliated Hospital of Harbin Medical University. Primary endpoint: Response Evaluation Criteria in Solid Tumors. Started Nov 2021; status: recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
liver cancerhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2100052768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052768.